Population-based study of lung function and incidence of heart failure hospitalisations

Gunnar Engström, Olle Melander, Bo Hedblad

Department of Clinical Sciences,
Lund University, Malmö
University Hospital, Sweden

Correspondence to
Professor Gunnar Engström,
Cardiovascular Epidemiology
Research Group, UMAS, CRC,
20502 Malmö, Sweden;
Gunnar.Engstrom@med.lu.se

Received 17 January 2010
Accepted 19 April 2010

ABSTRACT

Background Reduced forced expiratory volume (FEV₁) and forced vital capacity (FVC) are risk factors for myocardial infarction (MI) and stroke. However, the relationship with incidence of heart failure (HF) is incompletely known. This population-based study explored whether reduced FEV₁ or FVC is associated with the incidence of hospitalisation for HF.

Methods 20 998 men (mean age 43 years) with no history of MI or stroke were examined with spirometry in 1974–84. The incidence of hospitalisation due to HF was studied over a mean follow-up of 23 years in relation to age- and height-adjusted FEV₁ and FVC.

Results 725 incident HF hospitalisations occurred during the follow-up period, 503 of them without a previous or concurrent diagnosis of MI. In non-smokers the risk factor-adjusted hazard ratio (HR) for HF hospitalisation was 1.25 (95% CI 1.11 to 1.40) and 1.26 (95% CI 1.13 to 1.42), respectively, per 1SD lower FEV₁ and FVC. The corresponding risk factor-adjusted HRs in smokers were 1.32 (95% CI 1.21 to 1.45) and 1.22 (95% CI 1.11 to 1.33), respectively, for FEV₁ and FVC. This relationship was consistent in men with and without hypertension, in men above and below the median age of 44 years and for HF events without previous or concurrent MI. Exclusion of cases with a diagnosis of chronic obstructive pulmonary disease during the follow-up period did not substantially change the results.

Conclusion In this long-term population-based study of men, moderately reduced FEV₁ and FVC were associated with an increased incidence of hospitalisations due to HF.

INTRODUCTION

Reduced lung function, measured by forced expiratory volume in 1 s (FEV₁) or forced vital capacity (FVC), is a risk factor for cardiovascular disease (CVD). Low FEV₁ and FVC within the normal range have been associated with the incidence of myocardial infarction (MI), stroke and asymptomatic atherosclerosis in the carotid and leg arteries.^{1–6} However, whether low FEV₁ or FVC is similarly associated with the incidence of heart failure (HF) is unclear.

HF is a multifactorial disorder with several systemic manifestations which could be the result of different disease processes that reduce cardiac function.^{7–9} Reduced lung function is one of the systemic effects, and it has been known for many years that HF results in reduced lung volumes.^{10–12} However, the temporal and causal relationships between lung function and HF are unclear. In a population-based study of elderly people aged >65 years, low FEV₁ was associated with an increased incidence of HF independently of other major risk factors.¹³ Similar relationships were

reported from the Framingham study,¹⁰ but not in the study of 'Men born in 1913'.¹⁴ It is largely unknown whether moderately reduced FEV₁ or FVC in apparently healthy young or middle-aged subjects could be a risk factor for developing HF.

The Malmö Preventive Project includes approximately 21 000 apparently healthy men with information on lung function and other cardiovascular risk factors. The cohort was examined at a mean age of 43 years—that is, at an age when HF is very unusual in men from the general population. The purpose of this follow-up was to explore whether FEV₁ and FVC are associated with the incidence of hospitalisations due to HF.

METHODS

Between 1974 and 1984, 22 444 men participated in a screening programme for detection of individuals with a high risk for CVD.¹⁵ Complete birth cohorts from the city of Malmö were invited to a health examination which included blood tests and a comprehensive questionnaire. The participation rate was 71%. It has been reported that cardiovascular mortality was higher and that the incidence of non-fatal MI was lower in non-participants.¹⁵

Of the 22 444 men, information about FEV₁ and FVC was available in 21 185 men. Subjects with missing information about blood pressure (n=13), blood lipids (n=54) and body mass index (BMI) (n=2) were excluded. To reduce the possibility that pre-existing heart disease reduced the lung volumes, we also excluded men with a history of MI or stroke (n=114) and subjects with a hospital diagnosis of HF before the baseline examination (n=5). A total of 20 998 men remained after the exclusions. The mean (SD) age was 43.4 (6.6) years (range 27–61).

Baseline examinations

Subjects were categorised into smokers and non-smokers. The smokers were categorised into consumers of up to 9 cigarettes per day, 10–19 cigarettes per day and a daily consumption of ≥20 cigarettes.

BMI was calculated as weight/height² (kg/m²).

Blood pressure (mm Hg) was measured twice in the right arm after 10 min of rest. The average of two measurements was used. A sphygmomanometer and a rubber cuff of appropriate size were used. Use of antihypertensive medication was assessed in a questionnaire. Hypertension was defined as systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg and/or pharmacological treatment for hypertension.

Physical inactivity in spare time was assessed using the question: 'Are you mostly engaged in

sedentary activities in spare time, for example, watching TV, reading, going to the movies?'.¹⁶ Subjects who confirmed a doctor's diagnosis of angina pectoris or who used nitrates were considered to have angina pectoris.¹⁶

Blood samples were taken after an overnight fast. Leucocyte counts were analysed using an automatic counter according to the standard methods at the hospital laboratory. Serum cholesterol, triglycerides and blood glucose were similarly analysed with standard methods at the hospital laboratory. Men with fasting whole blood glucose ≥ 6.1 mmol/l and those who reported treatment for diabetes were considered diabetic. Information on diabetes was missing for 74 (0.4%) individuals. This group was coded in a separate category to keep them in the multivariate analysis.

High alcohol consumption was assessed by means of the modified shortened version of the Michigan Alcoholism Screening Test.¹⁷ Men with more than two (of nine) affirmative answers were considered to have high alcohol consumption.¹⁶

FVC and FEV₁ were measured using a Spirotron apparatus (Drägerwerk AG, Lübeck, Germany) with the subjects in a standing position without noseclips. Specially trained nurses performed the tests. One acceptable manoeuvre with respect to the subject's performance and cooperation was required. The volumes were standardised for age and height using equations derived from linear regressions of 3467 male never smokers in the present cohort.^{18, 19} The following equations were used:

Predicted FEV₁ (l) = $4.422 \times \text{height (m)} - 0.038 \times \text{age} - 2.48$

Predicted FVC (l) = $6.58 \times \text{height (m)} - 0.033 \times \text{age} - 5.54$

Predicted FEV₁/FVC (%) = $1.156 - 0.1556 \times \text{height (m)} - 0.002025 \times \text{age}$

Age and height were essentially unrelated to the lung volumes after adjustments. FEV₁ and FVC are expressed as percentage of the predicted values.

Occupation and marital status

Information on marital status and occupation was retrieved by data linkage with national census registers.²⁰ High and medium level non-manual workers and self-employed men were categorised as 'high' occupational groups. Low level non-manual workers, manual workers and unspecified occupational groups (early retired men, students, unemployed) were categorised as 'low' occupational groups. The subjects were further categorised into single (divorced, widowers or unmarried) men or married (married or cohabiting) men.²⁰ Information on occupation level and marital status was missing in 181 (0.9%) and 56 (0.3%) of the men, respectively. These groups were coded into separate categories to keep them in the multivariate analysis.

Follow-up

In the primary analysis, all men were followed from the baseline examination until first hospitalisation due to HF, death, emigration from Sweden or 31 December 2004, whichever came first. Subjects with a hospital discharge diagnosis of HF (codes 427.00, 427.10, 428.99, International Classification of Diseases, ICD-8), 428 (ICD-9) and I50 or I11.0 (ICD-10)) were considered to have HF if the diagnosis was listed as the primary diagnosis. In a secondary analysis, subjects with non-fatal MI were followed until the day of the infarction and censored thereafter. A non-fatal MI was defined as code 410 or I21 according to ICD-9 or ICD-10.

Since low lung function is a major risk factor for developing chronic obstructive pulmonary disease (COPD), and COPD hypothetically could increase the probability of being hospitalised and having a diagnosis of HF, an additional analysis was performed in which subjects who developed COPD were

followed until the first diagnosis of COPD, listed as one of the first three diagnoses,¹⁸ and censored after that.

The Swedish Hospital Discharge Register was used for case retrieval and the Swedish population register was used for information on emigration and mortality during the follow-up. A validation study has shown that a primary diagnosis of HF in the Swedish Hospital Discharge Register has a validity of 95%.²¹

Statistical analysis

One-way analysis of variance (for continuous variables) and logistic regression (for dichotomous variables) was used for cross-sectional analyses of the risk factor distribution over the quartiles of FEV₁. The Kaplan–Meier test with log rank statistics was used to study the incidence of HF hospitalisations for quartiles of lung function. Cox proportional hazards regression was used to calculate risk factor-adjusted hazard rates (HR). Cardiovascular risk factors that were associated with FEV₁ at the baseline examination were selected as covariates in the multivariate analysis. Age, cholesterol, triglycerides (log-normalised), systolic blood pressure and BMI were fitted as continuous variables. Smoking, antihypertensive treatment, high alcohol consumption and physical inactivity were fitted as dichotomous variables. Three categories were used for low occupation level, married/cohabiting and diabetes (yes, no, missing). The fit of the proportional hazards model was checked visually by plotting the incidence rates over time and by entering time-dependent variables into the model. The covariate-adjusted Cox analysis was performed separately in smokers and non-smokers. Finally, the relationship between lung function and HF was explored for cases without a history of MI during the follow-up period and after censoring men who were diagnosed with COPD before the onset of HF.

RESULTS

Study cohort

In terms of unadjusted volumes, mean $\pm$ SD FEV₁ was 3.7 ± 0.75 l and 3.4 ± 0.76 l, respectively, in non-smokers and smokers. FVC was 4.7 ± 0.89 l and 4.4 ± 0.90 l, respectively. Expressed as a percentage of the predicted values, mean $\pm$ SD FEV₁ was $99 \pm 17\%$ in non-smokers and $91 \pm 17\%$ in smokers, and mean $\pm$ SD FVC was $99 \pm 16\%$ in non-smokers and $94 \pm 16\%$ in smokers. FEV₁ was $94 \pm 18\%$, $91 \pm 17\%$ and $88 \pm 17\%$, respectively, in smokers with consumption of <10 , 10 – 19 and ≥ 20 cigarettes per day.

The baseline characteristics of the study population are shown in table 1 in relation to quartiles of FEV₁. All major cardiovascular risk factors showed significant relationships with FEV₁.

Incidence of HF in relation to lung function

During the mean follow-up period of 23.0 ± 5.5 years, 725 men were admitted to hospital with a primary diagnosis of HF. Of these, 222 had been admitted with a primary diagnosis of MI before the HF event. Low FEV₁ and low FVC were significantly associated with the incidence of HF. This relationship was consistent in smokers and non-smokers, also after adjustments for cardiovascular risk factors (figures 1 and 2 and table 2). FEV₁/FVC (% predicted) in the lowest quartile was associated with HF hospitalisations in smokers. There was no relationship between FEV₁/FVC and the incidence of HF in non-smokers.

A total of 503 cases had HF without MI before or concurrent with the diagnosis of HF. The relationship between low lung function and incidence of HF was even stronger for these cases (table 3).

Table 1 Baseline characteristics of the study cohort in relation to quartiles of forced expiratory volume in 1 s (FEV₁)

	Q4 (high)	Q3	Q2	Q1 (low)	P _{trend}	All men
N	5249	5250	5250	5249		20998
FEV ₁ , % predicted	>106	95–106	84–95	<84		95±18
Age, years	43.9±6.5	43.0±6.6	42.8±6.7	44.1±6.7	0.32	43.4±6.6
Height, cm	177±6.7	177±6.7	177±6.7	177±6.9	0.76	177±6.7
Current smoking, %	36.0	43.9	53.8	64.4	<0.001	49.5
>20 cigs/day, % of smokers	19.4	23.6	28.5	33.1	<0.001	27.3
Diabetes, %	3.9	4.6	4.2	6.7	<0.001	4.8
Systolic BP, mm Hg	127±14	127±14	126±15	128±16	<0.001	127±15
Diastolic BP, mm Hg	85.0±9.1	85.1±9.4	85.1±9.6	86.2±10	<0.001	85.4±10
Antihypertensive treatment, %	3.1	3.5	3.6	4.9	<0.001	3.8
Cholesterol, mmol/l	5.5±1.0	5.6±1.0	5.6±1.1	5.7±1.1	<0.001	5.6±1.1
Triglycerides, mmol/l†	1.21	1.27	1.33	1.42	<0.001	1.31
BMI, kg/m ²	24.5±3.0	24.6±3.2	24.6±3.3	24.9±3.7	<0.001	24.6±3.3
Physical inactivity, %	46.1	50.7	54.4	59.0	<0.001	52.6
Low occupation level, %	56.3	57.7	60.8	66.2	<0.001	60.2
Married, %	70.6	72.0	69.8	66.4	<0.001	69.7
High alcohol consumption, %	15.6	16.8	18.7	20.7	<0.001	18.0
Angina pectoris, %	1.0	1.0	1.0	2.0	<0.001	1.3
Leucocytes, 10 ⁹ /l*	5.7±1.8	5.9±1.9	6.2±2.0	6.5±2.1	<0.001	6.1±2.0

*Leucocyte measurements were available in a subcohort of 15 929 men.

†Triglycerides are shown as geometric means.

BMI, body mass index.

The death rates were also higher in subjects with low lung function. In non-smokers (1591 deaths), the death rates (per 1000 person-years) were 5.8, 5.7, 5.7 and 9.1, respectively, for the 4th, 3rd, 2nd and 1st quartiles of FEV₁. In smokers (2909 deaths) the death rates were 9.3, 10.6, 11.6 and 16.2, respectively, in the quartiles of FEV₁.

An additional analysis was performed in which patients were also censored if they had COPD listed as a hospital diagnosis during the follow-up period. A total of 263 incident cases of HF remained among the non-smokers and 371 cases remained among the smokers. After adjustments for risk factors, the relationship between FEV₁ and the incidence of HF was 1.16 per 1SD (95% CI 1.02 to 1.30) in non-smokers and 1.18 (95% CI 1.06 to 1.31) in smokers. The HRs for FVC were 1.19 per 1SD (95% CI 1.05 to 1.34) in non-smokers and 1.14 (95% CI 1.03 to 1.26) in smokers. FEV₁/FVC was not associated with HF in this analysis

in non-smokers (HR per 1SD 1.00; 95% CI 0.88 to 1.14) or smokers (HR 1.07; 95% CI 0.97 to 1.17).

Analyses stratified by hypertension and age

The relationships between FEV₁ and FVC, respectively, and the incidence of HF hospitalisations are shown in table 3, stratified by smoking, age and hypertension. The relationships with the incidence of HF were consistent in these subgroups.

The relationship between low lung function and the incidence of HF seemed to be even stronger for cases of HF without previous MI (table 3).

Adjustments for leucocyte concentrations

Information about leucocyte concentrations was available in a subgroup of 15 929 men, 586 of whom were admitted to hospital with HF during the follow-up period. This subgroup

Figure 1 Incidence of hospitalisations for heart failure in non-smokers in relation to quartiles of forced expiratory volume in 1 s.

Figure 2 Incidence of hospitalisations for heart failure in smokers in relation to quartiles of forced expiratory volume in 1 s.

Table 2 Incidence of hospitalisations for HF in relation to measures of lung function in non-smokers and smokers

	Q4 (high)	Q3	Q2	Q1 (low)	P _{trend}	HR per 1SD*
Non-smokers						
FEV ₁						
N	3359	2943	2428	1870		
HF (n)	79	63	63	77		
Age-adjusted	1.00	1.03 (0.74 to 1.44)	1.29 (0.93 to 1.80)	1.95 (1.42 to 2.66)	<0.001	
Risk factors	1.00	0.89 (0.64 to 1.25)	1.05 (0.75 to 1.47)	1.47 (1.07 to 2.02)	0.015	1.25 (1.11 to 1.40)
FVC						
N	3130	2860	2554	2056		
HF (n)	66	66	57	93		
Age-adjusted	1.00	1.22 (0.87 to 1.72)	1.22 (0.86 to 1.72)	2.30 (1.68 to 3.15)	<0.001	
Risk factors	1.00	1.16 (0.82 to 1.63)	1.02 (0.71 to 1.45)	1.72 (1.24 to 2.37)	0.003	1.26 (1.13 to 1.42)
FEV ₁ /FVC						
N	2909	2896	2652	2143		
HF (n)	82	69	65	66		
Age-adjusted	1.00	0.87 (0.63 to 1.20)	0.91 (0.66 to 1.26)	1.06 (0.77 to 1.47)	0.74	
Risk factors	1.00	0.87 (0.63 to 1.20)	0.90 (0.65 to 1.25)	1.11 (0.80 to 1.54)	0.58	1.05 (0.93 to 1.19)
Smokers						
FEV ₁						
N	1890	2307	2822	3379		
HF (n)	50	81	109	203		
Age-adjusted	1.00	1.46 (1.02 to 2.07)	1.61 (1.15 to 2.25)	2.41 (1.77 to 3.28)	<0.001	
Risk factors	1.00	1.35 (0.95 to 1.93)	1.52 (1.09 to 2.13)	2.05 (1.49 to 2.80)	<0.001	1.32 (1.21 to 1.45)
FVC						
N	2119	2390	2696	3193		
HF (n)	65	83	111	184		
Age-adjusted	1.00	1.19 (0.86 to 1.65)	1.47 (1.09 to 2.00)	1.91 (1.44 to 2.53)	<0.001	
Risk factors	1.00	1.13 (0.82 to 1.57)	1.36 (1.00 to 1.85)	1.51 (1.13 to 2.02)	0.002	1.22 (1.11 to 1.33)
FEV ₁ /FVC						
N	2340	2354	2598	3106		
HF (n)	96	82	98	167		
Age-adjusted	1.00	0.94 (0.70 to 1.27)	1.02 (0.77 to 1.36)	1.35 (1.05 to 1.74)	0.009	
Risk factors	1.00	0.94 (0.70 to 1.27)	1.07 (0.81 to 1.43)	1.44 (1.12 to 1.86)	<0.001	1.18 (1.09 to 1.28)

Risk factors included systolic BP, antihypertensive treatment, cigarettes (smokers only), cholesterol, triglycerides, body mass index, physical inactivity, occupation level, diabetes, angina, marital status and high alcohol intake.

Median (interquartile limits) are 95% (84, 106) for FEV₁, 97% (87, 107) for FVC and 99% (92, 105) for FEV₁/FVC.

*Hazard ratios (HR) per 1SD lower FEV₁ (18% of predicted values), FVC (16% of predicted values) or FEV₁/FVC (11% of predicted values).

FEV₁, forced expiratory volume in 1 s; FVC, forced vital capacity; HF, heart failure.

was somewhat older (43.7 ± 5.5 vs 42.5 ± 9.3 years) and more often smokers (51% vs 45%) than those without information on leucocytes. The relationship between FEV₁ and FVC, respectively, and the incidence of HF was only marginally reduced by adjustments for leucocytes, and the associations remained significant in smokers and non-smokers. For example, in non-smokers the HR for 1SD lower FEV₁ was 1.25 (95% CI 1.10 to 1.42) after adjustments for risk factors and 1.24 (95% CI 1.09 to 1.42) after further adjustments for leucocytes; the corresponding HRs for FVC were 1.26 (95% CI 1.11 to 1.44) and 1.26 (95% CI 1.10 to 1.44), respectively.

DISCUSSION

Even though reduced FEV₁ and FVC are well-known risk factors for CVD, the relationship between lung function and the incidence of HF is incompletely known. In this population-based study of men without a history of MI or stroke, reduced volumes of FEV₁ or FVC were significantly associated with the incidence of HF requiring admission to hospital. This relationship was consistent in smokers and non-smokers, in men with and without hypertension and in men above and below the median age of 44 years. Pulmonary obstruction as measured by the FEV₁/FVC ratio was associated with HF hospitalisations in smokers only.

The results are in accordance with a study of older subjects¹³ and the results from the Framingham study in which lung function was measured shortly before the HF diagnosis.¹⁰ Correlations between echocardiographic measures of left ventricular function and measures of airway obstruction were recently reported in a cross-sectional study.²² However, there was no relationship between lung function and the incidence of HF in the study 'Men Born in 1913'.¹⁵ After adjustments for age and sex, COPD was not associated with echocardiographic findings in the Copenhagen Heart Study.²³ The present results add to the current knowledge by demonstrating that reduced lung function is a very early risk factor which is predictive even in young age groups when very few people have cardiac failure, many years before the cases are hospitalised with HF. The present results persisted after adjustments for several risk factors including biological, socioeconomic and lifestyle factors, and the results could not be explained by relationships between lung function and the incidence of MI.

It has previously been shown that moderately reduced lung function is associated with the incidence of MI, stroke and subclinical atherosclerosis.¹⁻⁶ However, the relationships with the incidence of HF are more complex and involve some methodological issues that need to be discussed. Patients with HF and those with COPD often show similar symptoms, and

Table 3 Multivariate analysis of incidence of hospitalisations for HF in relation to FEV₁ and FVC by age and hypertension status

	Cases/subjects (n/n)	FEV ₁ (per 1SD)	FVC (per 1SD)
Non-smokers			
<45 years	54/5467	1.68 (1.23 to 2.30)	1.77 (1.31 to 2.39)
≥45 years	228/5133	1.19 (1.05 to 1.35)	1.19 (1.05 to 1.35)
Normal BP	69/5569	1.55 (1.26 to 1.92)	1.53 (1.23 to 1.90)
Hypertension	213/5031	1.15 (1.01 to 1.32)	1.18 (1.03 to 1.35)
HF, no MI*	207/10600	1.30 (1.14 to 1.49)	1.33 (1.17 to 1.52)
HF, after MI*	75/10600	1.11 (0.89 to 1.39)	1.09 (0.87 to 1.37)
Smokers			
<45 years	100/5220	1.34 (1.09 to 1.66)	1.22 (0.99 to 1.51)
≥45 years	343/5178	1.32 (1.19 to 1.46)	1.21 (1.09 to 1.35)
Normal BP	181/6532	1.36 (1.18 to 1.58)	1.27 (1.10 to 1.47)
Hypertension	262/3866	1.30 (1.16 to 1.47)	1.18 (1.04 to 1.33)
HF, no MI*	296/10398	1.38 (1.24 to 1.54)	1.22 (1.09 to 1.37)
HF, after MI*	147/10398	1.21 (1.03 to 1.42)	1.21 (1.03 to 1.41)

Presented as hazard ratios (per 1SD lower FEV₁ or FVC) adjusted for systolic BP, antihypertensive treatment, cigarettes (smokers only), cholesterol, triglycerides, body mass index, physical inactivity, occupation level, diabetes, angina, marital status and high alcohol intake.

*Incidence of HF without previous myocardial infarction (no MI) and with previous or concurrent MI (after MI).

FEV₁, forced expiratory volume in 1 s; FVC, forced vital capacity; HF, heart failure; MI, myocardial infarction.

misclassification of HF and lung disease is one potential cause of bias.^{24 25} Coexisting COPD could also increase the probability of hospitalisation for a patient with HF. However, since COPD is strongly linked to smoking, this potential misclassification bias would be much stronger in smokers than in non-smokers. A validation study using data from the Swedish Hospital Discharge Register showed that a diagnosis of HF had very high accuracy if it was listed as the primary diagnosis.²¹ To further reduce the risk of diagnostic misclassification and hospitalisation bias, we also performed an analysis in which men with a diagnosis of COPD were censored. FEV₁/FVC was no longer associated with HF in smokers, but the relationships between FEV₁, FVC and the incidence of HF were essentially the same. We therefore think it is unlikely that diagnostic misclassification could explain the results in this study.

Even though the relationship between reduced lung function and the incidence of CVD has been known for many years, the reason for this relationship is still unclear. Both FEV₁ and FVC showed significant relationships with the incidence of HF in this study. This suggests that the results are related to lung volume or reduced compliance of the lung or chest wall, rather than to airway obstruction which would affect FEV₁/FVC to a higher degree than FVC. Since the relationships were also clearly significant in young non-smokers (aged 27–44 years, mean 38 years), it is possible that the increased risk reflects traits which are established early in life or factors of genetic origin. Low birth weight has been associated with both increased cardiovascular risk and low FEV₁ later in life^{26 27} and could be a possible link between FEV₁ and CVD.

Ischaemic heart disease is a risk factor for HF and one question is whether this could explain the results. Men with a history of MI and stroke at baseline were excluded. The relationships were even stronger for HF cases without a previous or concurrent diagnosis of MI during the follow-up period. Hence, relationships between reduced lung function and clinical MI could not explain the results. However, many MIs are silent and it is possible that some incident cases of HF had a subclinical infarction.

Blood pressure is another major risk factor for HF. All analyses were adjusted for systolic blood pressure and antihypertensive treatment. We performed separate analyses of men with normal blood pressure, and low FEV₁ or FVC was also associated with the incidence of HF in this group. It is unlikely that differences with respect to blood pressure at baseline confounded the relationship between lung function and the incidence of HF. However, some studies have reported that low FVC could be a risk factor for developing hypertension and diabetes.^{28–30} In that case, development of hypertension and diabetes during the follow-up period could be part of the causal chain between low lung function and HF. This possibility cannot be excluded. It has also been shown that reduced FEV₁ is associated with increased 'beat-to-beat' variability of the systolic blood pressure, even within the normal range of FEV₁.³¹ Short-term variability in blood pressure is strongly related to the mechanical effects of breathing and variations in intrathoracic pressure and could therefore be related to lung function per se.³² Although blood pressure variability is a strong cardiovascular risk factor,³³ the role of high frequent 'beat-to-beat' variations is unclear. Although speculative, it is possible that increased blood pressure variability could increase the risk of HF in men with low FEV₁.

Increased cardiac size and increased pressure of the pulmonary circulation are two factors that reduce the lung volumes in patients with HF. One question is whether the results could be explained by reverse causation—that is, whether impaired lung function could be secondary to cardiac dysfunction. However, the men in this population study were rather young and HF in the absence of MI is very unusual at this age. The results persisted when the sample was restricted to men aged 44 years and younger. Only a few cases of HF occurred during the first 10 years of the follow-up period. The long time period between the baseline examination and the incidence of HF also reduces the possibility of reverse causation.

Recent studies have shown that systemic low-grade inflammation is associated with HF.^{16 34 35} Since low FEV₁ or FVC has been associated with raised plasma levels of various markers of inflammation, we performed a subgroup analysis of almost 16 000 men with adjustments for the leucocyte concentration. A high leucocyte concentration has been associated with the incidence of HF in this cohort.¹⁶ The results were largely unchanged after adjustments for leucocytes, which suggests that inflammation has no major role in the relationship between lung function and HF.

Some limitations should be acknowledged. Only middle-aged men were studied, and it is unclear whether the results could be generalised to all age groups and to women. FEV₁ and FVC were measured several years before the currently used guidelines for standardisation of spirometry were published and the examinations did not meet the standards of the recent guidelines. If anything, low precision of the lung function measurements should reduce the association with the incidence of HF. However, the validity is supported by previous studies from the present cohort which show that FEV₁ and FVC are strongly linked to cardiovascular as well as pulmonary diseases.^{18 19 30}

All cases were admitted to hospital with a primary diagnosis of HF, and it can be assumed that the cardiac disease was quite severe in most cases. We do not know to what extent lung function is associated with less severe forms of HF which are more likely to be treated in primary care. However, results from an echocardiographic follow-up of elderly subjects suggest that low FEV₁ is also associated with the development of less severe forms of HF.¹³ Another shortcoming is that we had limited

information about the cases with regard to the type and cause of cardiac dysfunction.

In conclusion, this study of comparatively young men without a history of MI or stroke showed that moderately reduced volumes of FEV₁ and FVC were associated with an increased incidence of HF requiring hospitalisation. This relationship was consistent in smokers and non-smokers, in men with and without hypertension and in men above and below the median age of 44 years.

Funding This study was supported by grants from the Swedish Heart and Lung Foundation, the Swedish Research Council, Lund University and Malmö University Hospital.

Competing interests GE is employed as a senior epidemiologist by AstraZeneca R&D.

Ethics approval This study was conducted with the approval of the regional ethics committee, Lund University, Sweden. The health service authority of Malmö approved and funded the screening programme. All participants gave informed consent. The data linkage with hospitalisation registers was approved by the regional ethics committee.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

1. Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. *Chest* 2005;**127**:1952–9.
2. Johnston AK, Mannino DM, Hagan GW, et al. Relationship between lung function impairment and incidence or recurrence of cardiovascular events in a middle-aged cohort. *Thorax* 2008;**63**:599–605.
3. Hole DJ, Watt GCM, Davey-Smith G, et al. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. *BMJ* 1996;**313**:711–15.
4. Engström G, Hedblad B, Valind S, et al. Asymptomatic leg and carotid atherosclerosis in smokers is related to degree of ventilatory capacity: longitudinal and cross-sectional results from 'Men born in 1914', Sweden. *Atherosclerosis* 2001;**155**:237–43.
5. Zureik M, Kauffmann F, Touboul PJ, et al. Association between peak expiratory flow and the development of carotid atherosclerotic plaques. *Arch Intern Med* 2001;**161**:1669–76.
6. Lange P, Nyboe J, Appleyard M, et al. Spirometric findings and mortality in never-smokers. *J Clin Epidemiol* 1990;**43**:867–73.
7. Cowie MR, Wood DA, Coats AJ, et al. Incidence and aetiology of heart failure: a population-based study. *Eur Heart J* 1999;**20**:421–8.
8. Butler J, Kalogeropoulos A, Georgiopoulos V, for the Health ABC Study. Incident heart failure prediction in the elderly: the Health ABC heart failure score. *Circ Heart Fail* 2008;**1**:125–33.
9. Wilhelmsen L, Rosengren A, Eriksson H, et al. Heart failure in the general population of men—morbidity, risk factors and prognosis. *J Intern Med* 2001;**249**:253–61.
10. Kannel WB, Seidman JM, Fercho W, et al. Vital capacity and congestive heart failure. The Framingham Study. *Circulation* 1974;**49**:1160–6.
11. Calhoun JA, Cullen GE, Harrison TR, et al. Studies in congestive heart failure: XIV. Orthopnea: its relation to ventilation, vital capacity, oxygen saturation and acid-base condition of arterial and jugular blood. *J Clin Invest* 1931;**10**:833–55.
12. Enright PL, Kronmal RA, Smith VE, et al. Reduced vital capacity in elderly persons with hypertension, coronary heart disease, or left ventricular hypertrophy. The Cardiovascular Health Study. *Chest* 1995;**107**:28–35.
13. Gottdiener JS, Arnold AM, Aurigemma GP, et al. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. *J Am Coll Cardiol* 2000;**35**:1628–37.
14. Eriksson H, Svärdsudd K, Larsson B, et al. Risk factors for heart failure in the general population: the study of men born in 1913. *Eur Heart J* 1989;**10**:647–56.
15. Berglund G, Nilsson P, Eriksson KF, et al. Long-term outcome of the Malmö preventive project: mortality and cardiovascular morbidity. *J Intern Med* 2000;**247**:19–29.
16. Engström G, Melander O, Hedblad B. Leukocyte count and incidence of hospitalizations due to heart failure. A population-based cohort study. *Circ Heart Fail* 2009;**2**:217–22.
17. Kristenson H, Trell E. Indicators of alcohol consumption: comparisons between a questionnaire (Mm-MAST), interviews and serum gamma-glutamyl transferase (GGT) in a health survey of middle-aged males. *Br J Addict* 1982;**77**:297–304.
18. Engström G, Segelstam N, Ekberg-Aronsson M, et al. Plasma markers of inflammation and incidence of hospitalisations for COPD: results from a population-based cohort study. *Thorax* 2009;**64**:211–15.
19. Ekberg-Aronsson M, Pehrsson K, Nilsson JA, et al. Mortality in GOLD stages of COPD and its dependence on symptoms of chronic bronchitis. *Respir Res* 2005;**6**:98.
20. Hedblad B, Jonsson S, Nilsson P, et al. Obesity and myocardial infarction: vulnerability related to occupational level and marital status. A 23-year follow-up of an urban male Swedish population. *J Intern Med* 2002;**252**:542–50.
21. Ingelsson E, Arnlov J, Sundström J, et al. The validity of a diagnosis of heart failure in a hospital discharge register. *Eur J Heart Fail* 2005;**7**:787–91.
22. Barr RG, Bluemke DA, Ahmed FS, et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. *N Engl J Med* 2010;**362**:217–27.
23. Lange P, Mogelvang R, Marott JL, et al. Cardiovascular morbidity in COPD: a study of the general population. *COPD* 2010;**7**:5–10.
24. Hawkins NM, Petrie MC, Jhund PS, et al. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. *Eur J Heart Fail* 2009;**11**:130–9.
25. Rutten FH, Cramer MJ, Lammers JW, et al. Heart failure and chronic obstructive pulmonary disease: an ignored combination? *Eur J Heart Fail* 2006;**8**:706–11.
26. Barker DJ, Godfrey KM, Fall C, et al. Relation of birth weight and childhood respiratory infection to adult lung function and death from chronic obstructive airways disease. *BMJ* 1991;**303**:671–5.
27. Barker DJ, Osmond C, Forsén TJ, et al. Trajectories of growth among children who have coronary events as adults. *N Engl J Med* 2005;**353**:1802–9.
28. Sparrow D, Weiss ST, Vokonas PS, et al. Forced vital capacity and the risk of hypertension. The Normative Aging Study. *Am J Epidemiol* 1988;**127**:734–41.
29. Engström G, Wollmer P, Valind S, et al. Blood pressure increase between 55 and 68 years of age is inversely related to lung function: longitudinal results from the cohort study 'Men born in 1914'. *J Hypertens* 2001;**19**:1203–8.
30. Engström G, Hedblad B, Nilsson P, et al. Lung function, insulin resistance and incidence of cardiovascular disease: a longitudinal cohort study. *J Intern Med* 2003;**253**:574–81.
31. Engström G, Gerhardsson de Verdier M, Dahlbäck M, et al. BP variability and cardiovascular autonomic function in relation to forced expiratory volume: a population-based study. *Chest* 2009;**136**:177–83.
32. Brychta RJ, Shiavi R, Robertson D, et al. A simplified two-component model of blood pressure fluctuation. *Am J Physiol Heart Circ Physiol* 2007;**292**:H1193–203.
33. Mancia G, Bombelli M, Facchetti R, et al. Long-term prognostic value of blood pressure variability in the general population: results of the Pressioni Arteriose Monitorate e Loro Associazioni Study. *Hypertension* 2007;**49**:1265–70.
34. Suzuki T, Katz R, Jenny NS, et al. Metabolic syndrome, inflammation, and the incident heart failure in the elderly: the cardiovascular health study. *Circ Heart Fail* 2008;**1**:242–8.
35. Vasan RS, Sullivan LM, Rouvenoff R, et al. Framingham Heart Study. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the framingham heart study. *Circulation* 2003;**107**:1486–91.